ELU42

ELU42 is a first-in-class, water-soluble, small molecule drug administered as a topical spray that modulates the Wnt signaling pathway and possesses bacteriostatic activity[1][7][9]. Inspired by research into "superhealer" mice that overexpress Wnt inhibitory proteins, ELU42 is designed to promote regenerative healing in chronic and acute wounds by mimicking this enhanced tissue repair mechanism[4]. It is in development primarily for the treatment of chronic open wounds, specifically targeting diabetic foot ulcers (DFUs), with potential applications for other wound types (e.g., third-degree burns, surgical incisions, elastic cartilage reconstruction, pulmonary fibrotic damage, and inflammatory skin diseases)[5][6]. The drug represents a paradigm shift from wound management to true healing, aiming to reduce scarring and enhance tissue elasticity[4]. Early preclinical work originated from academic research at Vanderbilt University[4].